POS0472 TREATMENT RESPONSE TO INTRAMUSCULAR STEROIDS IN PATIENTS LIVING WITH RHEUMATOID ARTHRITIS: AN EXPLORATORY ANALYSIS USING TRACKED DAILY SYMPTOMS

Background Current understanding of treatment response is largely based on patient recollection at infrequent clinic appointments, which introduces inaccuracies through recall error. Real-time patient-reported symptom data collected frequently following an intervention could improve our response, facilitating better clinical decision making. Objectives Our exploratory analysis reports a case-series patients who used the Remote Monitoring Rheumatoid Arthritis (REMORA) smartphone-app for daily tracking, evaluating their longitudinal pain-scores intramuscular (IM) steroids to determine duration and extent response. Methods We identified participating in REMORA study Nov 2021-Sep 2022 received IM steroid. Concomitant disease-modifying medications were noted. Daily pain scores (out 10) from 10 days preceding injection 8 weeks analysed. Analysis was definitions: [1] Pre-injection score: mean pain-score injection; [2] Response (Y/N): ≥1 day score <[1]; [3] start time: [4] End response: first date with ≥[1]; [5] duration: number between [4]; [6] Average during [5]; [7] Nadir lowest [8] improvement: difference [6]; [9] Maximum [7]. Results Thirty-two inclusion, whom 6 steroid injections. In total 9 injections given. ranged 3.33-9.29. Seven demonstrated 2 did not. Of responders, 1-54 (median days); average improvement 0.14-5.33 3.33); maximum 0.14-7.00 4.33). Table 1 summarises results. Figure demonstrates patterns each injection. 1. individual demographic Injection (patient number) Age (years) Sex (M/F) drugs period dose (mg) (Y/N) (days) (1) 30 M MTX 120 Y 7.33 4.00 3.00 3.33 4.33 MTX, SSZ 8.00 2.67 1.00 5.33 7.00 3 180 5.40 1.80 3.60 4.40 4 (2) 53 F HCQ 7 0.14 5 (3) 52 160 5.75 1.67 N 9.29 (4) 41 4.56 2.21 2.35 3.56 (5) 65 SSZ, 54 2.56 4.44 6.00 (6) 40 5.56 Range (Median ) (9) 3.33-9.29 (5.75) 1.80-4.00 (2.67) 1.00-4.00 (3.33) (4.33) MTX: Methotrexate; SSZ: Sulfasalazine; HCQ: Hydroxychloroquine concomitant therapies Conclusion Smartphone-based remote monitoring has potential care people living rheumatoid arthritis. this analysis, we novel means accurately assess using tracked data. The quantified all participants, typically imprecise relies recall. these preliminary results, shorter, smaller, than anticipated. across larger population may help identify responder characteristics, supporting more targeted therapeutic strategies. This significant implications high-cost such as biologics. Further work required develop consensus definitions disease activity time-series data, account effects drugs. REFERENCES: NIL. Acknowledgements: Disclosure Interests Mariam Al-Attar: None declared, Julie Gandrup Employee of: JG currently employed by UCB. completed before joining UCB., Sabine van der Veer: William Dixon: declared.